| ID Source | ID |
|---|---|
| PubMed CID | 6610310 |
| CHEMBL ID | 66620 |
| CHEBI ID | 93134 |
| SCHEMBL ID | 2458882 |
| Synonym |
|---|
| bdbm50038991 |
| benzo[1,3]dioxol-5-ylmethyl-(6-chloro-quinazolin-4-yl)-amine |
| BRD-K64746805-001-02-9 |
| BSPBIO_001464 |
| IDI1_033934 |
| BIO2_000184 |
| BIO2_000664 , |
| UPCMLD-DP008:001 |
| UPCMLD-DP008 |
| UPCMLD-DP008:002 |
| NCGC00161596-02 |
| NCGC00161596-01 |
| NCGC00161596-03 |
| KBIO2_002752 |
| KBIO3_000368 |
| KBIOSS_000184 |
| KBIOGR_000184 |
| KBIO2_005320 |
| KBIO2_000184 |
| KBIO3_000367 |
| NCGC00161596-04 |
| HMS1989J06 |
| CHEMBL66620 , |
| HMS1791J06 |
| HMS1361J06 |
| n-(1,3-benzodioxol-5-ylmethyl)-6-chloroquinazolin-4-amine |
| 150450-53-6 |
| 4-quinazolinamine, n-(1,3-benzodioxol-5-ylmethyl)-6-chloro- |
| mbcq |
| SCHEMBL2458882 |
| 4-(3,4-methylenedioxybenzyl)amino-6-chloroquinazoline |
| CNODHOSDWZLJGA-UHFFFAOYSA-N , |
| DTXSID60425013 |
| HMS3402J06 |
| CHEBI:93134 |
| mbcq, >=98% (hplc) |
| J-008707 |
| AKOS030551286 |
| 4-[[3,4-(methylenedioxy)benzyl]amino]-6-chloroquinazoline |
| n-(1,3-benzodioxol-5-ylmethyl)-6-chloro-4-quinazolinamine |
| Q27164854 |
| n-(benzo[d][1,3]dioxol-5-ylmethyl)-6-chloroquinazolin-4-amine |
| MS-24595 |
| HY-114672 |
| 4-((3,4-methylenedioxybenzyl)amino)-6-chloroquinazoline |
| CS-0063762 |
| Class | Description |
|---|---|
| quinazolines | Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| TDP1 protein | Homo sapiens (human) | Potency | 2.8371 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 39.8107 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 3.7199 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
| DNA polymerase kappa isoform 1 | Homo sapiens (human) | Potency | 16.8336 | 0.0316 | 22.3146 | 100.0000 | AID588579 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 3.5481 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| cGMP-dependent 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0000 | 1.7767 | 9.2000 | AID158580 |
| cGMP-specific 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | IC50 (µMol) | 0.0190 | 0.0000 | 1.1843 | 9.6140 | AID158584 |
| 3',5'-cyclic-AMP phosphodiesterase | Sus scrofa (pig) | IC50 (µMol) | 100.0000 | 0.0010 | 3.4002 | 6.4000 | AID158579 |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1A | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.2300 | 2.5105 | 10.0000 | AID158585 |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0000 | 2.1417 | 9.2000 | AID158585 |
| Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1C | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.2300 | 1.9814 | 9.0000 | AID158585 |
| Phosphodiesterase | Sus scrofa (pig) | IC50 (µMol) | 100.0000 | 0.6200 | 0.7315 | 0.8430 | AID158718 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID158718 | Inhibition of cGMP-inhibited PDE 3 from porcine aorta | 1994 | Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13 | Cyclic GMP phosphodiesterase inhibitors. 2. Requirement of 6-substitution of quinazoline derivatives for potent and selective inhibitory activity. |
| AID158585 | Inhibition of Ca++ calmodulin dependent-PDE 1 from porcine aorta | 1994 | Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13 | Cyclic GMP phosphodiesterase inhibitors. 2. Requirement of 6-substitution of quinazoline derivatives for potent and selective inhibitory activity. |
| AID158580 | Inhibition of cGMP stimulated-PDE 2 from porcine aorta | 1994 | Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13 | Cyclic GMP phosphodiesterase inhibitors. 2. Requirement of 6-substitution of quinazoline derivatives for potent and selective inhibitory activity. |
| AID158584 | Inhibitory activity against cGMP-phosphodiesterase from porcine aorta | 1994 | Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13 | Cyclic GMP phosphodiesterase inhibitors. 2. Requirement of 6-substitution of quinazoline derivatives for potent and selective inhibitory activity. |
| AID160676 | Relaxant effect on PGF2-alpha precontracted porcine coronary arteries | 1994 | Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13 | Cyclic GMP phosphodiesterase inhibitors. 2. Requirement of 6-substitution of quinazoline derivatives for potent and selective inhibitory activity. |
| AID158579 | Inhibition of cAMP specific-PDE 4 from porcine aorta | 1994 | Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13 | Cyclic GMP phosphodiesterase inhibitors. 2. Requirement of 6-substitution of quinazoline derivatives for potent and selective inhibitory activity. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| AID493017 | Wombat Data for BeliefDocking | 1994 | Journal of medicinal chemistry, Jun-24, Volume: 37, Issue:13 | Cyclic GMP phosphodiesterase inhibitors. 2. Requirement of 6-substitution of quinazoline derivatives for potent and selective inhibitory activity. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (13.07) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||